Shire Says Patent Settlements Didn't Delay Generic Adderall

Law360, New York (June 3, 2013, 6:30 PM EDT) -- Shire LLC on Friday urged a California federal court to throw out putative class allegations that the drug company stifled competition for Adderall XR through patent settlements and supply agreements with generic-drug makers, saying its conduct did not delay entry of a generic.

In a motion to dismiss, Shire raised a host of arguments as to why a putative antitrust class action brought against it should be tossed, including that the named plaintiff, Erin Shaffer, has no standing to challenge allegedly anti-competitive settlements Shire reached to...
To view the full article, register now.